



# INTEGRATED PROTEINS LIMITED

City Point, 5<sup>th</sup> Floor, Opp. Town Hall, Jamnagar – 361 001, Gujarat, India

Phone: (0288) 2551901 Fax: (0288) 2552566

Email ID: [ipl.complianceofficer@gmail.com](mailto:ipl.complianceofficer@gmail.com)

Website: [www.integratedproteins.com](http://www.integratedproteins.com)

CIN: L62013GJ1992PLC018426

28<sup>th</sup> May, 2025

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400001

**Scrip Code: 519606**

**Sub: Outcome of the meeting of the Board of Directors held on Wednesday, 28<sup>th</sup> May, 2025**

**Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015.**

Dear Sir/Madam,

With reference to above subject and in compliance with Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e., Wednesday, 28<sup>th</sup> May, 2025, at 04:00 p.m. and concluded on 5:15 p.m. *inter alia* considered and approved the following:

1. Considered, approved and adopted the Audited Financial Results for the Quarter and Financial Year ended on 31<sup>st</sup> March, 2025 along with the Auditor's Report and Certificate for unmodified opinion Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

These results have been duly reviewed by the Audit Committee and audited by M/s B. B. Gusani & Associates, Chartered Accountants (Firm Registration No. 140785W), Statutory Auditors of the Company.

*(The copies of the aforesaid Financial Results along with the Auditors' Reports thereon and Declaration on Unmodified Opinion on the Audit Report, on standalone basis, are enclosed herewith.)*

2. Reviewed business of the Company.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully



# **INTEGRATED PROTEINS LIMITED**

**City Point, 5<sup>th</sup> Floor, Opp. Town Hall, Jamnagar – 361 001, Gujarat, India**

Phone: (0288) 2551901 Fax: (0288) 2552566

Email ID: [ipl.complianceofficer@gmail.com](mailto:ipl.complianceofficer@gmail.com)

Website: [www.integratedproteins.com](http://www.integratedproteins.com)

CIN: L62013GJ1992PLC018426

**For Integrated Proteins Limited**

**Urvashi Gandhi**

**Company Secretary**

**Membership No.: A57163**



**INDEPENDENT AUDITOR'S REPORT**

**To Board of Directors of  
Integrated Proteins Limited**

**Independent Auditors Report on the Quarter and Year to date standalone financial results of Integrated Proteins Limited pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015**

**Opinion**

1. We have audited the accompanying standalone financial results of **Integrated Proteins Limited** (hereinafter referred to as "the company") for the year ended March 31, 2025 and the standalone statement of assets and liabilities and standalone statement of cash flows as at and for the year ended on that date, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('listing regulations').
2. In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:
  - (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
  - (ii) give a true and fair view in conformity with recognition and measurement principles laid down in applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") and other accounting principles generally accepted in India, of the net profit (including other comprehensive income) and other financial information of the company for the year ended March 31, 2025, and the standalone statement of assets and liabilities and standalone statement of cash flows as at and for the year ended on that date.

**Basis for Opinion**

3. We conducted our audit in accordance with Standards on Auditing (SAs) specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India ("the ICAI"). Our responsibilities under those standards are further described in the 'Auditor's Responsibilities for the Audit of Standalone Financial Results' section of our report. We are independent of the company in accordance with the code of ethics issued by the ICAI together with ethical requirements that are relevant to our audit of the standalone financial results under the provisions of the Act and Rules made thereunder, and we have fulfilled our ethical responsibilities in accordance with the requirements with these requirements and the Code of Ethics. We believe that the audit evidences obtained by us is sufficient and appropriate to provide a basis for our opinion.





### **Board of Directors' Responsibilities for the Standalone Financial Results**

4. These standalone financial results have been prepared on the basis of the annual standalone financial statements. The company's Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the company and the standalone statement of assets and liabilities and standalone statement of cash flows in accordance with recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant issues thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of accounting policies; making judgement and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give true and fair view and are free for material misstatement, whether due to fraud and error.
5. In preparing the standalone financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors of the Company is responsible for overseeing the financial reporting process of the Company.

### **Auditor's Responsibilities for the Audit of Standalone Financial Results**

7. Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatement can arise from a fraud or error and consider material, if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.
8. As part of an audit in accordance with the SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:





- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedure responsive to those risks, and obtain audit evidence that is sufficient and appropriate to our basis of opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud involves collusions, forgery, intentional omissions, misrepresentations, or override of internal control.
  - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
  - Evaluate the appropriateness of the accounting policies used and reasonableness of accounting estimates and related disclosures made by the Board of Directors.
  - Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on our audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the company to continue as a going concern. If we conclude that material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidences obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
  - Evaluate the overall presentation, structure and content of financial results including the disclosures and whether the standalone financial results represent the underlying transactions and events in the manner that achieves fair presentation.
9. We communicate with those charged with governance of the company regarding, among other matters, the planned scope of timing of the audit and significant audit findings, including significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear our independence, and wherever applicable, related safeguards.





**B.B. Gusani & Associates**  
Chartered Accountants

**CA BHARGAV B. GUSANI**  
M bhargavgusani77@gmail.com

**Other Matters**

10. The standalone financial results include the results for the quarter ended March 31, 2025 and March 31, 2024 being the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the respective financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

**For, B B Gusani and Associates**  
**Chartered Accountants**

  
**Bhargav B Gusani**  
**Proprietor**  
**Membership No. 120710**  
**FRN: 140785W**  
**UDIN: 25120710BMHTQG1678**  
**Date: 28/05/2025**  
**Place: Jamnagar**



# INTEGRATED PROTEINS LIMITED

CIN: 162013G1992PLC018426

REGISTERED OFFICE: CITY POINT, OPP- TOWN HALL JAMANAGAR GUJRAT 361008

## Standalone Statement of Audited Financial Results for the Quarter/ Year Ended 31-03-2025

(Rs. In Lakh, except per share data)


| Particulars  | Quarter Ended   |              |              | Year Ended      |              |
|--|-----------------|--------------|--------------|-----------------|--------------|
|  | 31-03-2025      | 31-12-2024   | 31-03-2024   | 31-03-2025      | 31-03-2024   |
| A Date of start of reporting period  | 01-01-2025      | 01-10-2024   | 01-01-2024   | 01-04-2024      | 01-04-2023   |
| B Date of end of reporting period  | 31-03-2025      | 31-12-2024   | 31-03-2024   | 31-03-2025      | 31-03-2024   |
| C Whether results are audited or unaudited   | Audited         | Unaudited    | Audited      | Audited         | Audited      |
| <b>Part I</b>  |                 |              |              |                 |              |
| <b>I Revenue From Operations</b>   |                 |              |              |                 |              |
| Net sales or Revenue from Operations   | 2,148.67        | 0.96         | 23.74        | 2,149.63        | 23.74        |
| <b>II Other Income</b>   | 3.89            | 11.81        | 13.14        | 23.74           | 24.89        |
| <b>III Total Income (I + II)</b>   | <b>2,152.55</b> | <b>12.77</b> | <b>36.88</b> | <b>2,173.36</b> | <b>48.63</b> |
| <b>IV Expenses</b>   |                 |              |              |                 |              |
| (a) Cost of materials consumed   | -               | -            | -            | -               | -            |
| (b) Purchases of stock-in-trade  | 2,102.50        | -            | 22.23        | 2,102.50        | 22.23        |
| (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade  | -               | -            | -            | -               | -            |
| (d) Employee benefit expense   | -               | 0.31         | 4.63         | 1.63            | 6.07         |
| (e) Finance Costs  | -               | -            | -            | -               | -            |
| (f) Depreciation and amortisation expense  | 0.00            | -            | 0.48         | 0.96            | 2.64         |
| (g) Other Expenses   | 22.65           | 4.40         | 1.87         | 36.33           | 7.29         |
| <b>Total expenses</b>  | <b>2,125.15</b> | <b>4.71</b>  | <b>29.21</b> | <b>2,141.42</b> | <b>38.23</b> |
| <b>V Profit (loss) before Exceptional and Extraordinary Items and</b>  | <b>27.40</b>    | <b>8.06</b>  | <b>7.67</b>  | <b>31.94</b>    | <b>10.40</b> |
| <b>VI Exceptional Items</b>  |                 |              |              |                 |              |
| <b>VIII Profit (loss) before Tax (VII-VIII)</b>  | <b>27.40</b>    | <b>8.06</b>  | <b>7.67</b>  | <b>31.94</b>    | <b>10.40</b> |
| <b>X Tax Expense</b>   |                 |              |              |                 |              |
| (a) Current Tax  | 6.90            | 1.14         | 1.70         | 8.04            | 2.41         |
| (Less)- MAT Credit   | -               | -            | -            | -               | -            |
| Current Tax Expense Relating to Prior years  | -               | -            | -            | -               | -            |
| (b) Deferred Tax (Asset)/Liabilities   | (0.79)          | -            | 3.75         | (1.10)          | (0.95)       |
| <b>XI Net Profit/Loss for the period from Continuing Operations (IX-X)</b>   | <b>21.29</b>    | <b>6.92</b>  | <b>2.22</b>  | <b>25.00</b>    | <b>8.93</b>  |
| <b>XII Profit (Loss) from Discontinuing Operations</b>   | -               | -            | -            | -               | -            |
| <b>XIII Tax Expenses of Discontinuing Operations</b>   | -               | -            | -            | -               | -            |
| <b>XIV Net Profit (Loss) from Discontinuing Operations after tax (XII-XIII)</b>  | -               | -            | -            | -               | -            |
| <b>XV Profit (Loss) for the period (XI+XIV)</b>  | <b>21.29</b>    | <b>6.92</b>  | <b>2.22</b>  | <b>25.00</b>    | <b>8.93</b>  |
| <b>XVI Other Comprehensive Income</b>  |                 |              |              |                 |              |
| a. i). Amount of item that will not be reclassified to profit or loss  |                 |              |              |                 |              |
| ii). Income tax relating to items that will not be reclassified to profit or loss  |                 |              |              |                 |              |
| b i). Item that will be reclassified to profit or loss   |                 |              |              |                 |              |
| ii). Income tax relating to items that will be reclassified to profit or loss  |                 |              |              |                 |              |
| <b>XVII Total Comprehensive income</b>   | <b>0.00</b>     | <b>0.00</b>  | <b>0.00</b>  | <b>0.00</b>     | <b>0.00</b>  |
| <b>Total Comprehensive income [Comprising Profit for the Period (After tax) and Other comprehensive income ] (XV+XVII)</b> | <b>21.29</b>    | <b>6.92</b>  | <b>2.22</b>  | <b>25.00</b>    | <b>8.93</b>  |
| <b>XVIII Details of equity share capital</b>   |                 |              |              |                 |              |
| Paid-up equity share capital (Face Value of Rs. 10/- per equity share)   | 352.02          | 352.02       | 352.02       | 352.02          | 352.02       |
| Face value of equity share capital (Per Share)   | Rs. 10/-        | Rs. 10/-     | Rs. 10/-     | Rs. 10/-        | Rs. 10/-     |
| <b>XIX Earnings per share (Not Annualized for Year ended)</b>  | <b>0.60</b>     | <b>0.20</b>  | <b>0.06</b>  | <b>0.71</b>     | <b>0.25</b>  |
| (a) <b>Earnings per share Continuing Operation ( Not Annualised for Year ended )</b>                                       |                 |              |              |                 |              |
| Basic earnings per share before extraordinary items  | 0.60            | 0.20         | 0.06         | 0.71            | 0.25         |
| Diluted earnings per share before extraordinary items  | 0.60            | 0.20         | 0.06         | 0.71            | 0.25         |
| (b) <b>Earnings per share Discontinuing Operation ( Not Annualised for Year ended )</b>                                    |                 |              |              |                 |              |
| Basic earnings per share after extraordinary items   | 0.00            | 0.00         | 0.00         | 0.00            | 0.00         |
| Diluted earnings per share after extraordinary items   | 0.00            | 0.00         | 0.00         | 0.00            | 0.00         |
| (c) <b>Earnings per share (Not Annualised for Year ended )</b>   |                 |              |              |                 |              |
| Basic earnings per share before extraordinary items  | 0.60            | 0.20         | 0.06         | 0.71            | 0.25         |
| Diluted earnings per share before extraordinary items  | 0.60            | 0.20         | 0.06         | 0.71            | 0.25         |

**Notes:-**

**Notes to Standalone Audited financials results for the year ended 31st March 2025:**

- 1 The above said financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective Meetings held on 28th May 2025.
- 2 The Statutory Auditors have carried out the statutory audit of the above financial results of the company and have expressed an unmodified opinion on the Statements is prepared in accordance with the requirement of Accounting Standards (AS) specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014.
- 3 The above Audited financial results have been prepared in accordance with Companies (Accounting Standards) Rules, 2006 (AS) as amended, prescribed under Section 125 to 133 of Companies Act, 2013, read with relevant rules.
- 4 The Company has single reportable business segment. Hence, no separate information for segment wise disclosure is given in accordance with the requirements of Indian Accounting Standard (Ind AS) 108 - "Operating Segments".
- 5 Earning Per share : Earning Per share is calculated on the weighted average of the share capital received by the company.
- 6 Statement of Assets and Liabilities and cashflow statement as on 31st March 2025 is enclosed herewith.
- 7 The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

Date :- 28-05-2025  
Place :- Jamnagar

  
**Ganesh Dharmeshbhai Doshi**  
 Managing Director  
 DIN: 10848249



**INTEGRATED PROTEINS LIMITED**

CIN: L62013GJ1992PLC018426

REGISTERED OFFICE: CITY POINT, OPP- TOWN HALL JAMANAGAR GUJRAT 361008

(Rupees in Lakhs)

Standalone Statement of Balance Sheet as at 31st March, 2025

| Particulars  | As at            | As at            |
|--|------------------|------------------|
|  | 31st March, 2025 | 31st March, 2024 |
| <b>ASSETS</b>  |                  |                  |
| <b>Non-current assets</b>  |                  |                  |
| (a) Property, plant and equipment                                      | 4.64             | 41.50            |
| (b) Capital work-in-progress   | -                | -                |
| (c) Other Intangible Assets  | -                | -                |
| (d) Financial assets   | -                | -                |
| (i) Investments  | 0.03             | 15.29            |
| (ii) Trade receivables   | -                | -                |
| (iii) Loan   | -                | 174.00           |
| (e) Deferred Tax Assets  | -                | -                |
| (f) Other non-current asset  | 0.70             | 33.10            |
|  | -                | -                |
| <b>Total non-current assets</b>  | <b>5.38</b>      | <b>263.89</b>    |
| <b>Current assets</b>  |                  |                  |
| (a) Inventories  | -                | -                |
| (b) Financial assets   | -                | -                |
| (i) Trade receivables  | -                | -                |
| (ii) Cash and cash equivalents   | 8.73             | 6.15             |
| (iii) Loan   | -                | -                |
| (iv) Other financial asset   | -                | -                |
| (c) Income/Current tax assets (net)                                    | -                | -                |
| (c) Other current assets   | 3,223.12         | 3.78             |
| <b>Total current assets</b>  | <b>3,231.85</b>  | <b>9.93</b>      |
|  |                  |                  |
| <b>TOTAL ASSETS</b>  | <b>3,237.23</b>  | <b>273.82</b>    |
|  |                  |                  |
| <b>EQUITY AND LIABILITIES</b>  |                  |                  |
| <b>Equity</b>  |                  |                  |
| (a) Equity share capital   | 352.02           | 352.02           |
| (b) Other equity   | 1,659.79         | (91.10)          |
| <b>Total equity</b>  | <b>2,011.81</b>  | <b>260.92</b>    |
| <b>Non-current liabilities</b>   |                  |                  |
| (a) Financial liabilities  | -                | -                |
| (i) Borrowings   | -                | 3.50             |
| (b) Deffered tax liability (net)                                       | -                | 1.10             |
| <b>Total non current liabilities</b>                                   | <b>-</b>         | <b>4.60</b>      |
| <b>Current liabilities</b>   |                  |                  |
| (a) Financial liabilities  |                  |                  |
| (i) Borrowings   | 389.55           | -                |
| (ii) Trade payable   | -                | -                |
| 1. Dues of micro enterprises and small enterprises                     | -                | -                |
| 2. Dues of creditor other than micro enterprises and small enterprises | 800.31           | 1.29             |
| (iii) Other financial liabilities                                      | -                | -                |
| (b) Provision  | -                | -                |
| (c) Income/Current tax liabilities (net)                               | -                | -                |
| (d) Other current liabilities  | 35.56            | 7.00             |
| <b>Total current liabilities</b>                                       | <b>1,225.43</b>  | <b>8.29</b>      |
|  |                  |                  |
| <b>TOTAL EQUITY AND LIABILITIES</b>                                    | <b>3,237.23</b>  | <b>273.82</b>    |

FOR Integrated Proteins Limited

Karanj Dharmeshbhai Doshi  
Managing Director  
DIN: 10848249Date :- 28-05-2025  
Place :- Jamnagar

**INTEGRATED PROTEINS LIMITED**

CIN: L62013GJ1992PLC018426

REGISTERED OFFICE: CITY POINT, OPP- TOWN HALL JAMANAGAR GUJRAT 361008

(Rupees in Lakhs)

Standalone Cash Flow Statement for the year ended 31st March 2025

| S.No.     | Particulars  | Year ended<br>31st March, 2025 | Year ended<br>31st March, 2024 |
|-----------|--|--------------------------------|--------------------------------|
| <b>A)</b> | <b>Cash flow from operating activities</b>                           |                                |                                |
|           | Profit before taxation   | 31.94                          | 10.40                          |
|           | Adjustment for :   | -                              | -                              |
|           | Depreciation and amortisation  | 0.96                           | 2.64                           |
|           | Finance cost   | -                              | -                              |
|           | Interest income  | (15.30)                        | (15.00)                        |
|           | Profit on Sale of Fixed Assets                                       | (6.70)                         | -                              |
|           | Dividend Income  | -                              | -                              |
|           | <b>Operating profit/(loss) before working capital changes</b>        | <b>10.90</b>                   | <b>(1.96)</b>                  |
|           | Adjustment for :   |                                |                                |
|           | Increase/ (Decrease) in trade payables                               | 799.02                         | (4.37)                         |
|           | Increase/ (Decrease) in other current liabilities                    | 28.56                          | 2.83                           |
|           | Decrease/ (Increase) in other current Assets                         | (3,219.34)                     | (0.03)                         |
|           | Decrease/ (Increase) in Loan & Advances                              | 174.00                         | -                              |
|           | Decrease/ (Increase) other current assets                            | -                              | -                              |
|           | Decrease/ (Increase) in trade receivables                            | -                              | -                              |
|           | Provision  | -                              | -                              |
|           |  | <b>(2,217.76)</b>              | <b>(1.57)</b>                  |
|           | <b>Cash Generated from operations</b>                                | <b>(2,206.86)</b>              | <b>(3.53)</b>                  |
|           | Taxes paid (net)   | 8.04                           | 2.41                           |
|           | <b>Net cash flow from/(used in) operating activities (A)</b>         | <b>(2,214.89)</b>              | <b>(5.94)</b>                  |
| <b>B)</b> | <b>Cash from investing activities</b>                                |                                |                                |
|           | Movements in Investments   | 15.26                          | 5.05                           |
|           | Sale of property, plant and equipment                                | 42.60                          | 4.25                           |
|           | Purchase of property, plant and equipment                            | -                              | -                              |
|           | Movements in Other Non current Assest                                | 32.40                          | (9.50)                         |
|           | Interest income  | 15.30                          | 15.00                          |
|           | <b>Net cash used in investing activities (B)</b>                     | <b>105.55</b>                  | <b>14.80</b>                   |
| <b>C)</b> | <b>Cash flow from financing activities</b>                           |                                |                                |
|           | Issue of share capital   | 1,725.87                       | -                              |
|           | Proceeds from long-term borrowings                                   | (3.50)                         | -                              |
|           | Proceeds from short-term borrowings                                  | 389.55                         | (15.63)                        |
|           | Finance cost paid  | -                              | -                              |
|           | <b>Net cash flow from financing activities (C)</b>                   | <b>2,111.92</b>                | <b>(15.63)</b>                 |
| <b>D)</b> | <b>Net increase/ (decrease) in cash and cash equivalents (A+B+C)</b> | <b>2.58</b>                    | <b>(6.77)</b>                  |
| <b>E)</b> | <b>Cash and cash equivalents as at the beginning of the year</b>     | <b>6.15</b>                    | <b>12.92</b>                   |
| <b>F)</b> | <b>Cash and cash equivalents as at the end of the year</b>           | <b>8.73</b>                    | <b>6.15</b>                    |
|           | Balance with banks   | 1.02                           | 5.82                           |
|           | Cash in hand   | 7.71                           | 0.33                           |
|           | <b>Total</b>   | <b>8.73</b>                    | <b>6.15</b>                    |

FOR Integrated Proteins Limited

Karanj Dharmeshbhai Doshi  
Managing Director  
DIN: 10848249Date :- 28-05-2025  
Place :- Jamnagar

# INTEGRATED PROTEINS LIMITED

City Point, 5<sup>th</sup> Floor, Opp. Town Hall, Jamnagar – 361 001, Gujarat, India

Phone: (0288) 2551901 Fax: (0288) 2552566

Email ID: [ipl.complianceofficer@gmail.com](mailto:ipl.complianceofficer@gmail.com)

Website: [www.integratedproteins.com](http://www.integratedproteins.com)

CIN: L62013GJ1992PLC018426

(Rupees in lakhs)

ANNEXURE-A

## Statement on deviation / variation in utilisation of funds raised

|   |   |                    |  |  |  |
|---|---|--------------------|--|--|--|
| <b>Name of listed entity</b>  | Integrated Proteins Limited                                 |                    |  |  |  |
| <b>Mode of Fund Raising</b>   | <b>Public Issues / Rights Issues / Preferential</b>         | Preferential Issue |  |  |  |
| <b>Date of Raising Funds</b>  | 24/01/2025, 28/01/2025, 01/02/2025, 03/02/2025 & 04/02/2025 |                    |  |  |  |
| <b>Amount Raised</b>  | Rs 1744.88 lakhs  |                    |  |  |  |
| <b>Report filed for Quarter ended</b>   | Mar-25  |                    |  |  |  |
| <b>Monitoring Agency</b>  | <b>applicable / not applicable</b>                          | N.A.               |  |  |  |
| <b>Monitoring Agency Name, if applicable</b>  | N.A.  |                    |  |  |  |
| <b>Is there a Deviation / Variation in use of funds raised</b>  | Yes / No  | No                 |  |  |  |
| <b>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</b> | N.A.  |                    |  |  |  |
| <b>If Yes, Date of shareholder Approval</b>   | N.A.  |                    |  |  |  |
| <b>Explanation for the Deviation / Variation</b>  | N.A.  |                    |  |  |  |
| <b>Comments of the Audit Committee after review</b>   | Nil   |                    |  |  |  |
| <b>Comments of the auditors, if any</b>   | Nil   |                    |  |  |  |
| <b>Objects for which funds have been raised and where there has been a deviation, in the following table</b>                    |   |                    |  |  |  |

| Original Object  | Modified Object, if any | Original Allocation (Rupees in lakhs)  | Modified allocation, if any | Funds Utilised (Rupees in lakhs) | Amount of Deviation / Variation for the quarter according to applicable object | Remarks if any |
|--|-------------------------|--|-----------------------------|----------------------------------|--|----------------|
| The proceeds of the Preferential Issue shall be utilized for capital expenditure, acquisition in the same line of business, repayment of borrowings of the Company, expansion plans including investments in subsidiaries, working capital requirement, exploring new initiatives, meeting future funding requirements, general corporate purposes and such other purpose as the Board may decide. | N.A.                    | 1)Rs. 1058.50 lakhs for capital expenditure<br>2)Rs. 667.38 lakhs<br>For exploring new initiatives | N.A.                        | Rs. 1725.88 lakhs                | N.A.   |                |

### Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or  
 (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or  
 (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

For, Integrated Proteins Limited

  
 Karan Chharmeshbhai Doshi  
 Managing Director  
 DIN: 10848249





# INTEGRATED PROTEINS LIMITED

City Point, 5<sup>th</sup> Floor, Opp. Town Hall, Jamnagar – 361 001, Gujarat, India

Phone: (0288) 2551901 Fax: (0288) 2552566

Email ID: [ipl.complianceofficer@gmail.com](mailto:ipl.complianceofficer@gmail.com)

Website: [www.integratedproteins.com](http://www.integratedproteins.com)

CIN: L62013GJ1992PLC018426

28<sup>th</sup> May, 2025

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400001

**Scrip Code: 519606**

**Sub: Declaration pursuant to Regulation 33(3) (d) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

With reference to above, we hereby state that the statutory Auditor of the Company M/s B. B. Gusani & Associates, Chartered Accountants (Firm Registration No. 140785W), have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company for the quarter and year ended 31<sup>st</sup> March, 2025 in Compliance with the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take the same on your record and oblige.

Thanking you,

Yours faithfully

**For Integrated Proteins Limited**

**Urvashi Gandhi**

**Company Secretary**

**Membership No.: A57163**



# INTEGRATED PROTEINS LIMITED

City Point, 5<sup>th</sup> Floor, Opp. Town Hall, Jamnagar – 361 001, Gujarat, India

Phone: (0288) 2551901 Fax: (0288) 2552566

Email ID: [ipl.complianceofficer@gmail.com](mailto:ipl.complianceofficer@gmail.com)

Website: [www.integratedproteins.com](http://www.integratedproteins.com)

CIN: L62013GJ1992PLC018426

- B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC: ATTACHED HEREWITH AND MARKED AS ANNEXURE-A**
- C. DISCLOSURE OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES: NOT APPLICABLE**

| Sr. No. | Particulars   | In INR Crore |
|---------|---|--------------|
| 1.      | Loans / revolving facilities like cash credit from banks / financial institutions         |              |
| A       | Total amount outstanding as on date   | 0            |
| B       | Of the total amount outstanding, amount of default as on date                             | 0            |
| 2.      | Unlisted debt securities i.e. NCDs and NCRPS  |              |
| A       | Total amount outstanding as on date   | 0            |
| B       | Of the total amount outstanding, amount of default as on date                             | 0            |
| 3.      | Total financial indebtedness of the listed entity including short-term and long-term debt | 0            |

- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2<sup>nd</sup> and 4<sup>th</sup> quarter): Not Applicable**
- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (Applicable only for Annual Filing i.e., 4<sup>th</sup> quarter): NOT APPLICABLE**